{"id":68311,"date":"2026-06-16T14:59:24","date_gmt":"2026-06-16T06:59:24","guid":{"rendered":"https:\/\/flcube.com\/?p=68311"},"modified":"2026-06-16T14:59:25","modified_gmt":"2026-06-16T06:59:25","slug":"bms-secures-nmpa-approval-for-sotyktu-in-psoriatic-arthritis-first-selective-tyk2-inhibitor-expands-china-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68311","title":{"rendered":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bristol-Myers Squibb<\/strong> (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>) announced that <strong>China&#8217;s National Medical Products Administration (NMPA)<\/strong> has granted approval for <strong>Sotyktu (deucravacitinib)<\/strong> for use in <strong>adult patients with active psoriatic arthritis (PsA)<\/strong> who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New Indication Approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sotyktu (deucravacitinib) \u2013 oral selective TYK2 allosteric inhibitor<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Active psoriatic arthritis (inadequate response\/intolerance to DMARDs)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>Week of June 16, 2026<\/td><\/tr><tr><td><strong>Previous China Approval<\/strong><\/td><td>Moderate-to-severe plaque psoriasis (October 2023)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Deucravacitinib \u2013 first-in-class, highly selective allosteric TYK2 inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> Tyrosine kinase 2 (TYK2) \u2013 member of the JAK family involved in inflammatory signaling<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Unique allosteric binding mechanism provides high selectivity, potentially improving safety profile compared to pan-JAK inhibitors<\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> Represents a new class of small molecule oral targeted therapies for autoimmune conditions<\/li>\n\n\n\n<li><strong>Dual Indication Status:<\/strong> First selective TYK2 allosteric inhibitor studied in clinical trials for both plaque psoriasis and psoriatic arthritis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-amp-evidence-base\" class=\"wp-block-heading\">Clinical Development &amp; Evidence Base<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Approval Status (China)<\/th><th>Global Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Moderate-to-Severe Plaque Psoriasis<\/strong><\/td><td>Approved October 2023<\/td><td>Approved in US, EU, Japan, and other major markets<\/td><\/tr><tr><td><strong>Active Psoriatic Arthritis<\/strong><\/td><td>Approved June 2026<\/td><td>Phase III trials completed; regulatory reviews ongoing globally<\/td><\/tr><tr><td><strong>Additional Indications Under Study<\/strong><\/td><td>Lupus, inflammatory bowel disease<\/td><td>Various stages of clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The PsA approval is supported by robust Phase III clinical trial data demonstrating significant improvements in signs and symptoms of psoriatic arthritis, including joint pain, swelling, and physical function, compared to placebo.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PsA Market Opportunity:<\/strong> China&#8217;s psoriatic arthritis market estimated at USD 800 million annually, with significant unmet need given limited treatment options beyond TNF inhibitors and conventional DMARDs<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Sotyktu represents the first oral targeted therapy specifically approved for PsA in China with a novel mechanism of action distinct from existing biologics and JAK inhibitors<\/li>\n\n\n\n<li><strong>Commercial Synergy:<\/strong> Dual approval for both psoriasis and PsA enables comprehensive treatment approach for patients with both conditions, which co-occur in approximately 30% of psoriasis patients<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project peak annual sales of USD 1.2\u20131.8 billion globally across both indications by 2028, with China representing 15\u201320% of total revenue<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">BMS&#8217;s successful expansion of Sotyktu&#8217;s indications in China reinforces the company&#8217;s strategic focus on immunology and demonstrates the growing acceptance of novel targeted therapies in the Chinese market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial expectations for Sotyktu (deucravacitinib). Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement decisions, and execution of BMS&#8217;s commercial strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,429,428,849,15,33],"class_list":["post-68311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-bms","tag-bristol-myers-squibb","tag-nyse-bmy","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68311\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68311\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T06:59:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T06:59:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications\",\"datePublished\":\"2026-06-16T06:59:24+00:00\",\"dateModified\":\"2026-06-16T06:59:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1606.webp\",\"keywords\":[\"Auto-immune\",\"BMS\",\"Bristol-Myers Squibb\",\"NYSE: BMY\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68311#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68311\",\"name\":\"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1606.webp\",\"datePublished\":\"2026-06-16T06:59:24+00:00\",\"dateModified\":\"2026-06-16T06:59:25+00:00\",\"description\":\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China's National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68311\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1606.webp\",\"width\":1080,\"height\":608,\"caption\":\"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68311#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China's National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68311","og_locale":"en_US","og_type":"article","og_title":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications","og_description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China's National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.","og_url":"https:\/\/flcube.com\/?p=68311","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T06:59:24+00:00","article_modified_time":"2026-06-16T06:59:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68311#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68311"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications","datePublished":"2026-06-16T06:59:24+00:00","dateModified":"2026-06-16T06:59:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68311"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68311#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp","keywords":["Auto-immune","BMS","Bristol-Myers Squibb","NYSE: BMY","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68311#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68311","url":"https:\/\/flcube.com\/?p=68311","name":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68311#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68311#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp","datePublished":"2026-06-16T06:59:24+00:00","dateModified":"2026-06-16T06:59:25+00:00","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China's National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68311#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68311"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68311#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp","width":1080,"height":608,"caption":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68311#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis \u2013 First Selective TYK2 Inhibitor Expands China Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68311"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68311\/revisions"}],"predecessor-version":[{"id":68314,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68311\/revisions\/68314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68312"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}